Nik Hauser Selected Research

HHS 5

3/2016

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nik Hauser Research Topics

Disease

5	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2010
2	Neoplasms (Cancer) 08/2017 - 04/2014
1	Sudden Infant Death (SID) 03/2016
1	Suppuration 02/2012
1	Abscess 02/2012
1	Convalescence 09/2010
1	Infections 09/2010
1	Liver Failure 01/2010
1	Acute Liver Failure (Fulminant Hepatic Failure) 01/2010
1	Neoplasm Metastasis (Metastasis) 01/2010

Drug/Important Bio-Agent (IBA)

1	Trastuzumab (Herceptin)FDA Link 03/2016
1	HHS 5IBA 03/2016
1	ferric oxide (iron oxide)IBA 04/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2012
1	Fluorouracil (Carac)FDA LinkGeneric 01/2010
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2010

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2010
1	Segmental Mastectomy (Lumpectomy) 08/2017
1	Operative Surgical Procedures 04/2014
1	Mastectomy (Mammectomy) 03/2014
1	Catheters 02/2012
1	Hysterectomy 09/2010
1	Drug Therapy (Chemotherapy) 01/2010